What is the current guideline for BP controle in Acute ICH? Give me authentic guideline from valid source
Reading File
Finding Sources
Searching PubMed
"intracerebral hemorrhage" AND "blood pressure" AND "guideline"
Searching the Web
AHA ASA 2022 2023 guideline blood pressure management acute intracerebral hemorrhage ICH
Reading Web Page
blood pressure management acute intracerebral hemorrhage SBP target treatment
Finding Sources
Reading Article
Reading File
Reading File
I now have comprehensive data from three authoritative sources. Here is a complete, evidence-based answer:
BP Control in Acute Intracerebral Hemorrhage (ICH) — Current Guidelines
Primary Sources
- 2022 AHA/ASA Guideline — Greenberg SM et al., Stroke 2022; DOI: 10.1161/STR.0000000000000407 (PMID: 35579034) — the most comprehensive dedicated ICH guideline
- 2025 AHA/ACC Hypertension Guideline — published in Circulation 2025; DOI: 10.1161/CIR.0000000000001356 — updated ICH-specific BP recommendations incorporating INTERACT-3
2022 AHA/ASA ICH Guideline — BP Recommendations
Acute BP Lowering (Presentation to ≤72 hours)
| Scenario | Recommendation | Class / LOE |
|---|---|---|
| SBP 150–220 mmHg, mild-moderate ICH | Lower SBP to target 140 mmHg, maintain 130–150 mmHg range | Class 2b / C-LD |
| SBP >150 mmHg, mild-moderate ICH | SBP <130 mmHg is potentially harmful — avoid | Class 3: Harm / B-R |
| SBP >220 mmHg | Use continuous IV infusion + close monitoring to lower SBP | Class 2a |
| Large/severe ICH or requiring surgical decompression | Safety and efficacy of intensive BP lowering not well established | Class 3: Harm / B-R |
Key Principles (2022 AHA/ASA)
- Initiate treatment as soon as possible after ICH
- Use smooth, continuous, sustained BP control — avoid peaks and BP variability
- Maintain CPP ≥60–70 mmHg in patients with large ICH, elevated ICP, or compromised CPP
- SBP target 110–139 mmHg (ATACH-2 protocol) showed no added benefit and increased renal adverse events
2025 AHA/ACC Hypertension Guideline — Updated ICH Recommendations
The 2025 guideline updates the ICH section (Section 5.3.9.1) with two key recommendations:
| Recommendation | Class / LOE |
|---|---|
| For adults with acute spontaneous ICH presenting with SBP 150–220 mmHg: immediately lower SBP to 130 to <140 mmHg for at least 7 days to improve functional outcomes; stop antihypertensives if SBP <130 mmHg | COR 2a (NEW) |
| Careful titration to ensure smooth, non-labile, sustained BP control — avoiding peaks and large SBP variability — can be beneficial for functional outcomes | COR 2a (REVISED) |
This represents a tightening of the target compared to 2022 (now explicitly 130–<140 mmHg for ≥7 days), driven by INTERACT-2, INTERACT-3, and updated meta-analyses.
Evidence Base
| Trial | Key Finding |
|---|---|
| INTERACT-2 (NEJM 2013) | SBP <140 mmHg improved secondary functional outcomes (mRS) vs. <180 mmHg; mean achieved SBP ~150 mmHg in intensive group |
| ATACH-2 (NEJM 2016) | SBP 110–139 mmHg vs. 140–179 mmHg — no significant difference in primary outcome; increased renal adverse events in intensive group |
| INTERACT-3 (2023) | Early intensive SBP <140 mmHg (as part of a bundle with glucose/fever/coagulation control) maintained for 7 days → significantly improved long-term functional outcome vs. usual care |
| Meta-analyses | Consistent signal favoring SBP 130–140 mmHg range; going below 130 mmHg negates benefit |
Practical Summary (Bedside)
SBP on presentation → Action
──────────────────────────────────────────────────────
<150 mmHg → No acute intensive lowering needed
150–220 mmHg (mild-mod) → Target SBP 130–<140 mmHg within 1 hour, maintain ≥7 days
STOP antihypertensives if SBP drops <130 mmHg
>220 mmHg → IV continuous infusion (e.g., nicardipine, labetalol,
clevidipine) with arterial line monitoring
Large ICH / surgical case → Individualize; evidence insufficient for intensive lowering
Preferred IV agents: Nicardipine (most titratable), Labetalol, Clevidipine, Hydralazine (less preferred — reflex tachycardia, unpredictable)
What to Avoid
- SBP <130 mmHg — potentially harmful (increased renal adverse events; negates benefit per ATACH-2 and INTERACT-2 secondary analyses)
- Rapid, abrupt, or labile BP reductions — BP variability independently predicts worse outcomes (INTERACT-2 post-hoc)
- Sodium nitroprusside — increases ICP; generally avoided in ICH
Sources: 2022 AHA/ASA ICH Guideline (PMID: 35579034); 2025 AHA/ACC Hypertension Guideline, Section 5.3.9.1; Goldman-Cecil Medicine 26e; Bradley and Daroff's Neurology in Clinical Practice.
This is a shared conversation. Sign in to Orris to start your own chat.